Market Cap | 45.05M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -53.12M | Forward P/E | -0.41 | EPS next Y | - | 50D Avg Chg | -16.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 7.00% |
Dividend | N/A | Price/Book | 0.50 | EPS next 5Y | 18.30% | 52W High Chg | -54.00% |
Recommedations | 3.00 | Quick Ratio | 5.85 | Shares Outstanding | 43.28M | 52W Low Chg | 130.00% |
Insider Own | 13.74% | ROA | -16.50% | Shares Float | 34.45M | Beta | 0.85 |
Inst Own | 25.24% | ROE | -79.38% | Shares Shorted/Prior | 1.96M/1.93M | Price | 1.24 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 277,406 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 12 | Volume | 80,149 | Change | 2.48% |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Lamond David | Director Director | Dec 12 | Buy | 1.02 | 67,881 | 69,239 | 2,347,545 | 12/14/23 |
Lamond David | Director Director | Dec 05 | Buy | 1.01 | 57,369 | 57,943 | 2,279,664 | 12/07/23 |
Lamond David | Director Director | Nov 29 | Buy | 0.94 | 43,134 | 40,546 | 2,222,295 | 12/01/23 |
Lamond David | Director Director | Aug 30 | Buy | 1.32 | 82,052 | 108,309 | 2,179,161 | 08/31/23 |
Lamond David | Director Director | Aug 15 | Buy | 1.3 | 250,000 | 325,000 | 2,097,109 | 08/17/23 |
Thye Dirk | Chief Executive Offi.. Chief Executive Officer | Aug 08 | Buy | 1.24 | 80,000 | 99,200 | 360,911 | 08/09/23 |
Hannah Brendan | Chief Business Offic.. Chief Business Officer | Aug 08 | Buy | 1.22 | 71,762 | 87,550 | 201,555 | 08/09/23 |
McLoughlin Margaret | Director Director | Aug 08 | Buy | 1.23 | 8,000 | 9,840 | 8,000 | 08/09/23 |
McDowell Caryn Gordon | Chief Legal & Adm. O.. Chief Legal & Adm. Officer | Jun 06 | Sell | 2.86 | 10,800 | 30,888 | 122,500 | 06/08/22 |
McLoughlin Margaret | Director Director | Oct 08 | Option | 17 | 1,000 | 17,000 | 1,000 | 10/12/21 |
McLoughlin Margaret | Director Director | Oct 08 | Sell | 88.93 | 1,000 | 88,930 | 10/12/21 | |
McLoughlin Margaret | Director Director | Aug 18 | Sell | 96.62 | 6,000 | 579,720 | 08/18/21 | |
McLoughlin Margaret | Director Director | Aug 18 | Option | 17 | 6,000 | 102,000 | 6,000 | 08/18/21 |